300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Mobile
Retail
Marketplace
Film
Payments
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Belarus
Finland
Italy
Algeria
Hungary
Grenada
Israel
Honduras
Lithuania
Liechtenstein
Cambodia
Iceland
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Enso Ventures, VC Fund

Enso Ventures

VC Fund

London, United Kingdom

Enso Ventures is a private investment and project management company that specializes in making selective equity investments in high-technology and bio-tech companies

Total investments:
8
Last investment:
Lead investor:
13%

Last updated:

Industries Enso Ventures invests in

BiotechnologyTherapeuticsBiopharmaHealth CareLife Science

Stages Enso Ventures invests in

Series ASeries B

Countries Enso Ventures invests in

United StatesUnited Kingdom

Round sizes

Series A $2.6M–$14MSeries B $5M–$14M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2.6M–$14M
Series B
$5M–$14M

Investment Focus

Industry

  • Biotechnology 6 (75%)
  • Therapeutics 4 (50%)
  • Biopharma 3 (38%)
  • Health Care 3 (38%)
  • Life Science 2 (25%)
See all 11 industries →

Stage

  • Series A 4 (50%)
  • Series B 4 (50%)

Country

  • United States 6 (75%)
  • United Kingdom 1 (13%)

Team

NameTitleInvestmentsLinksEmail
Nikolay Danilov
Nikolay Danilov Managing Director
Managing Director Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Cognitive Geology Cognitive Geology
Founded in 2014, Cognitive Geology operates as a specialist software provider for the oil industry. $2.6M / Series A / Oct 06, 2017
NeuroVia NeuroVia
NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD. $14M / Series A / Jul 20, 2017
Cavion Cavion
Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3).Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, theywere the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers.Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Series A / Jan 06, 2017
Galera Therapeutics Galera Therapeutics
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. $5M / Series B / Feb 03, 2016
Seres Therapeutics Seres Therapeutics
Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbioticmicrobiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. $10M / Series B / May 23, 2014
Axcella Axcella
Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates inmuscle, neurodegenerative, and liver conditions. Series B / Dec 11, 2013
Seres Therapeutics Seres Therapeutics
Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbioticmicrobiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. $10.5M / Series A / Nov 21, 2013
Egalet Egalet
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and hasoptimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids. $14.3M / Series B / May 07, 2012

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Mobile
Retail
Marketplace
Film
Payments
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Belarus
Finland
Italy
Algeria
Hungary
Grenada
Israel
Honduras
Lithuania
Liechtenstein
Cambodia
Iceland
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Enso Ventures invest in?

Enso Ventures invests primarily in Biotechnology, Therapeutics and Biopharma startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Enso Ventures invest in?

Enso Ventures typically joins rounds of $2.6M–$14M at Series A and $5M–$14M at Series B. These are whole funding-round sizes, not Enso Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Enso Ventures took part in.

How do I contact Enso Ventures?

Public channels for Enso Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Enso Ventures?

The team at Enso Ventures includes Nikolay Danilov (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Enso Ventures Enso Ventures Find emails